Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$801000.0.

  • Integra Lifesciences Holdings' Exchange Rate Effect fell 11033.95% to -$801000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 1459.06%. This contributed to the annual value of -$6.5 million for FY2024, which is 26621.24% down from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Exchange Rate Effect stood at -$801000.0 for Q3 2025, which was down 11033.95% from $12.7 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Exchange Rate Effect high stood at $12.7 million for Q2 2025, and its period low was -$10.7 million during Q3 2022.
  • Its 5-year average for Exchange Rate Effect is -$335157.9, with a median of -$801000.0 in 2025.
  • In the last 5 years, Integra Lifesciences Holdings' Exchange Rate Effect tumbled by 62966.92% in 2024 and then surged by 122693.33% in 2025.
  • Integra Lifesciences Holdings' Exchange Rate Effect (Quarter) stood at $904000.0 in 2021, then skyrocketed by 1217.37% to $11.9 million in 2022, then crashed by 32.5% to $8.0 million in 2023, then crashed by 201.04% to -$8.1 million in 2024, then skyrocketed by 90.14% to -$801000.0 in 2025.
  • Its last three reported values are -$801000.0 in Q3 2025, $12.7 million for Q2 2025, and $4.5 million during Q1 2025.